PTC Therapeutics (PTCT) Misses Q3 EPS by 69c

PTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($1.76), $0.69 worse than the analyst estimate of ($1.07). Revenue for the quarter came in at $196.58 million versus the consensus estimate of $210.19 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Home Depot beats estimates, reaffirms fiscal 2026 guidance
• EXL closes $1 billion credit facility, up from $600 million